TMCI - Treace Medical Concepts, Inc. Stock Price, Fair Value and News

11.49USD-0.05 (-0.43%)Delayed as of 17 Apr 2024, 01:59 pm ET

Market Summary

USD11.49-0.05

Delayedas of 17 Apr 2024, 01:59 pm

-0.43%

TMCI Alerts

1 major insider sales recently.

TMCI Stock Price

View Fullscreen

TMCI RSI Chart

TMCI Valuation

Market Cap

712.7M

Price/Earnings (Trailing)

-14.39

Price/Sales (Trailing)

3.81

Price/Free Cashflow

-15.48

TMCI Price/Sales (Trailing)

TMCI Profitability

Return on Equity

-35.91%

Return on Assets

-19.66%

Free Cashflow Yield

-6.46%

TMCI Fundamentals

TMCI Revenue

Revenue (TTM)

187.1M

Rev. Growth (Yr)

25%

Rev. Growth (Qtr)

52.64%

TMCI Earnings

Earnings (TTM)

-49.5M

Earnings Growth (Yr)

-42.36%

Earnings Growth (Qtr)

64.15%

Breaking Down TMCI Revenue

52 Week Range

11.4427.70

(Low)(High)

Last 7 days

-7.4%

Last 30 days

-2.9%

Last 90 days

-7.9%

Trailing 12 Months

-55.3%

How does TMCI drawdown profile look like?

TMCI Financial Health

Current Ratio

4.4

Debt/Equity

0.38

Debt/Cashflow

-0.65

TMCI Investor Care

Shares Dilution (1Y)

11.12%

Diluted EPS (TTM)

-0.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	155.0M	167.0M	174.7M	187.1M
2022	104.8M	114.1M	125.5M	141.8M
2021	64.8M	77.7M	85.1M	94.4M
2020	43.9M	48.4M	52.9M	57.4M
2019	0	0	0	39.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Treace Medical Concepts, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 10, 2024	scanlan sean f.	sold (taxes)	-	-	-1,396	chief innovation officer
Mar 10, 2024	berutti aaron	sold (taxes)	-	-	-1,815	svp, sales
Mar 10, 2024	elder scot michael	sold (taxes)	-	-	-1,666	chief legl & comp off, corpsec
Mar 10, 2024	treace john t.	sold (taxes)	-	-	-5,021	chief executive officer
Mar 10, 2024	hair mark	sold (taxes)	-	-	-4,088	chief financial officer
Mar 08, 2024	hair mark	sold (taxes)	-	-	-1,067	chief financial officer
Mar 08, 2024	scanlan sean f.	sold (taxes)	-	-	-389	chief innovation officer
Mar 08, 2024	elder scot michael	sold (taxes)	-	-	-169	chief legl & comp off, corpsec
Mar 08, 2024	berutti aaron	sold (taxes)	-	-	-711	svp, sales
Mar 08, 2024	treace john t.	sold (taxes)	-	-	-2,064	chief executive officer

Which funds bought or sold TMCI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	reduced	-3.6	-42,432	3,145,860	0.01%
Apr 05, 2024	CWM, LLC	unchanged	-	1,000	43,000	-%
Apr 05, 2024	Davis Capital Management	unchanged	-	-63.00	3,125	-%
Apr 05, 2024	NBC SECURITIES, INC.	unchanged	-	-	11,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	133	955	1,710	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	added	100	44,199	90,818	0.04%
Mar 11, 2024	VANGUARD GROUP INC	added	2.49	-179,609	54,745,800	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	479	7,414,720	9,014,810	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	-9,284	286,582	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	reduced	-31.82	-8,101,860	15,942,700	0.36%

Are Funds Buying or Selling TMCI?

Are funds buying TMCI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TMCI

No. of Funds

TMCI Alerts

1 major insider sales recently.

Unveiling Treace Medical Concepts, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	alliancebernstein l.p.	0.1%	62,130	SC 13G/A
Feb 13, 2024	vanguard group inc	6.96%	4,293,789	SC 13G/A
Feb 09, 2024	treace john t.	17.7%	10,903,466	SC 13G/A
Jan 29, 2024	blackrock inc.	6.0%	3,691,901	SC 13G
Feb 14, 2023	alliancebernstein l.p.	5.8%	3,196,422	SC 13G
Feb 13, 2023	treace john r	4.3%	2,385,033	SC 13G/A
Feb 13, 2023	treace john t.	19.6%	10,865,584	SC 13G/A
Feb 09, 2023	vanguard group inc	5.90%	3,276,849	SC 13G
Feb 11, 2022	treace john t.	20.2%	10,746,709	SC 13G
Feb 11, 2022	treace john r	6.4%	3,410,043	SC 13G

Recent SEC filings of Treace Medical Concepts, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 02, 2024	ARS	ARS
Apr 02, 2024	DEF 14A	DEF 14A
Apr 02, 2024	DEFA14A	DEFA14A
Mar 29, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Feb 27, 2024	8-K	Current Report

Peers (Alternatives to Treace Medical Concepts, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	189.6B	40.1B	-5.40%	4.53%	33.12	4.73	-8.12%	-17.45%
BDX	66.7B	19.5B	-2.42%	-9.87%	53.13	3.42	4.02%	-22.04%
ALGN	22.9B	3.9B	-2.94%	-12.25%	51.49	5.93	3.42%	23.09%
BAX	20.1B	14.8B	-4.93%	-7.94%	7.56	1.36	2.12%	209.17%
MID-CAP
HSIC	9.2B	12.3B	-4.49%	-14.03%	22	0.74	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.69%	15.70%	32.17	2.62	4.97%	18.89%
BIO	8.5B	2.7B	-12.27%	-39.23%	-13.41	3.2	-4.68%	82.43%
XRAY	6.4B	4.0B	-6.21%	-24.72%	-47.49	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-0.75%	15.36%	-565.58	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-5.91%	-4.69%	11.86	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.61%	-18.37%	-1.88	0.4	7.73%	-1066.14%
ANIK	380.0M	166.7M	0.59%	-11.05%	-4.6	2.28	6.67%	-456.34%
ANGO	260.4M	324.0M	21.04%	-28.41%	-1.35	0.8	-3.19%	-337.41%
APYX	48.2M	52.3M	-22.35%	-53.67%	-2.57	0.92	17.61%	19.28%
AEMD	3.8M	3.7M	-16.76%	269.23%	-0.31	1.01	5.77%	8.23%

Treace Medical Concepts, Inc. News

Latest updates

Treace Medical Concepts, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	52.6%	62.00	41.00	42.00	42.00	50.00	33.00	30.00	29.00	33.00	22.00	21.00	19.00	24.00	14.00	8.00	11.00	-
Gross Profit	54.9%	51.00	33.00	34.00	34.00	41.00	27.00	25.00	24.00	28.00	17.00	17.00	15.00	19.00	11.00	6.00	9.00	-
Operating Expenses	13.7%	58.00	51.00	47.00	48.00	44.00	38.00	37.00	32.00	34.00	23.00	21.00	17.00	15.00	11.00	7.00	10.00	-
S&GA Expenses	19.0%	40.00	34.00	34.00	34.00	30.00	26.00	27.00	22.00	23.00	16.00	14.00	12.00	11.00	8.00	5.00	7.00	-
R&D Expenses	-4.6%	4.00	4.00	4.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	-
Interest Expenses	0.6%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	-
Net Income	64.2%	-6.28	-17.52	-12.27	-13.45	-4.41	-12.13	-17.23	-9.04	-6.62	-6.42	-5.08	-2.43	3.00	-2.65	-1.97	-1.61	-
Net Income Margin	3.0%	-0.26*	-0.27*	-0.25*	-0.30*	-0.30*	-0.36*	-0.34*	-0.26*	-0.22*	-0.13*	-0.10*	-0.07*	-	-	-	-	-
Free Cashflow	86.8%	-1.72	-13.01	-12.57	-18.74	-7.64	-13.34	-15.77	-8.68	-4.69	-10.16	-4.45	-0.60	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	4.8%	252	240	250	249	159	156	159	147	141	138	142	37.00	42.00
Current Assets	6.0%	198	187	198	223	133	128	135	127	138	135	141	36.00	41.00
Cash Equivalents	78.4%	13.00	7.00	12.00	30.00	19.00	89.00	102	98.00	106	109	120	16.00	18.00
Inventory	-0.2%	29.00	29.00	26.00	23.00	19.00	17.00	13.00	11.00	11.00	10.00	8.00	7.00	8.00
Net PPE	3.5%	22.00	22.00	19.00	16.00	15.00	14.00	9.00	4.00	3.00	2.00	1.00	1.00	1.00
Goodwill	0%	13.00	13.00	13.00	-	-	-	-	-	-	-	-	-	-
Liabilities	11.2%	114	103	100	92.00	98.00	94.00	87.00	60.00	48.00	40.00	39.00	38.00	41.00
Current Liabilities	35.8%	45.00	33.00	30.00	23.00	30.00	23.00	17.00	15.00	18.00	11.00	10.00	9.00	12.00
Long Term Debt	0.1%	53.00	53.00	53.00	53.00	53.00	53.00	53.00	29.00	29.00	29.00	29.00	29.00	29.00
LT Debt, Non Current	0.1%	53.00	53.00	53.00	53.00	53.00	53.00	53.00	29.00	29.00	29.00	29.00	29.00	29.00
Shareholder's Equity	0.1%	138	138	150	158	61.00	62.00	72.00	87.00	93.00	97.00	103	-	1.00
Retained Earnings	-4.9%	-134	-127	-110	-98.17	-84.72	-80.30	-68.20	-50.90	-41.90	-35.29	-28.87	-23.78	-21.35
Additional Paid-In Capital	2.3%	272	266	261	256	145	142	140	138	135	133	132	15.00	14.00
Shares Outstanding	0.2%	62.00	62.00	62.00	61.00	56.00	55.00	55.00	55.00	48.00	53.00	49.00	38.00	-
Float	-	-	-	1,224	-	-	-	526	-	-	-	1.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	105.6%	532	-9,507	-8,300	-17,300	-5,348	-7,493	-10,566	-7,241	-3,752	-9,241	-3,754	-446	2,442	-4,202	-1,845	-895	-
Share Based Compensation	13.1%	5,872	5,192	3,596	2,692	2,470	2,269	1,963	1,409	1,293	839	875	402	337	125	248	209	-
Cashflow From Investing	8.9%	5,007	4,597	-10,423	-80,480	-64,012	-5,857	-5,168	-1,481	-900	-939	-670	-196	-88.00	-58.00	-249	-674	-
Cashflow From Financing	3.8%	165	159	1,180	107,879	297	353	18,784	1,372	1,026	41.00	107,804	-1,219	323	9,351	1,796	33.00	-

TMCI Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 187,118	$ 141,838	$ 94,419
Cost of goods sold	35,181	25,532	16,888
Gross profit	151,937	116,306	77,531
Operating expenses
Sales and marketing	140,894	104,567	65,405
Research and development	15,440	13,584	10,204
General and administrative	47,031	32,999	18,432
Total operating expenses	203,365	151,150	94,041
Loss from operations	(51,428)	(34,844)	(16,510)
Interest income	6,726	1,313	17
Interest expense	(5,167)	(4,398)	(4,060)
Debt extinguishment loss	0	(4,483)	0
Other income, net	342	(403)	1
Other non-operating income (expense), net	1,901	(7,971)	(4,042)
Net loss	(49,527)	(42,815)	(20,552)
Convertible preferred stock cumulative and undeclared dividends	0	0	(196)
Net loss attributable to common stockholders	(49,527)	(42,815)	(20,748)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	190	(27)	0
Comprehensive loss	$ (49,337)	$ (42,842)	$ (20,748)
Net loss per share attributable to common stockholders, basic	$ (0.81)	$ (0.77)	$ (0.43)
Net loss per share attributable to common stockholders, diluted	$ (0.81)	$ (0.77)	$ (0.43)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	60,852,153	55,276,834	48,415,679
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	60,852,153	55,276,834	48,415,679

TMCI Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 12,982	$ 19,473
Marketable securities, short-term	110,216	61,779
Accounts receivable, net of allowance for doubtful accounts of $980 and $735 as of December 31, 2023 and 2022, respectively	38,063	29,196
Inventories	29,245	19,330
Prepaid expenses and other current assets	7,853	3,624
Total current assets	198,359	133,402
Property and equipment, net	22,298	15,338
Intangible assets, net of accumulated amortization of $475 and $0 as of December 31, 2023 and December 31, 2022, respectively	9,025	0
Goodwill	12,815	0
Operating lease right-of-use assets	9,264	10,138
Other non-current assets	146	146
Total assets	251,907	159,024
Current liabilities
Accounts payable	11,835	8,668
Accrued liabilities	10,458	6,216
Accrued commissions	10,759	7,356
Accrued compensation	7,549	7,666
Other liabilities	4,432	339
Total current liabilities	45,033	30,245
Long-term debt, net of discount of $992 and $1,289 as of December 31, 2023 and 2022, respectively	53,008	52,711
Operating lease liabilities, net of current portion	15,891	15,539
Other long-term liabilities	37	0
Total liabilities	113,969	98,495
Stockholders’ equity
Preferred stock, $0.001 par value, 5,000,000 shares authorized as of December 31,2023 and December 31, 2022; 0 shares issued and outstanding as of December 31,2023 and December 31, 2022	0	0
Common stock, $0.001 par value, 300,000,000 shares authorized; 61,749,654 issued and outstanding as of December 31, 2023; 300,000,000 shares authorized; 55,628,208 issued and outstanding as of December 31, 2022	62	55
Additional paid-in capital	271,973	145,221
Accumulated deficit	(134,247)	(84,720)
Accumulated other comprehensive (loss) incom	163	(27)
Treasury stock, at cost; 1,218 and 0 shares as of December 31, 2023 and December 31, 2022	(13)	0
Total stockholders’ equity	137,938	60,529
Total liabilities and stockholders’ equity	$ 251,907	$ 159,024

About Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision; and Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

CEO	Mr. John T. Treace
WEBSITE	treace.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	423

Treace Medical Concepts, Inc. Frequently Asked Questions

What is the ticker symbol for Treace Medical Concepts, Inc.? What does TMCI stand for in stocks?

TMCI is the stock ticker symbol of Treace Medical Concepts, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Treace Medical Concepts, Inc. (TMCI)?

As of Tue Apr 16 2024, market cap of Treace Medical Concepts, Inc. is 712.65 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TMCI stock?

You can check TMCI's fair value in chart for subscribers.

What is the fair value of TMCI stock?

You can check TMCI's fair value in chart for subscribers. The fair value of Treace Medical Concepts, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Treace Medical Concepts, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TMCI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Treace Medical Concepts, Inc. a good stock to buy?

The fair value guage provides a quick view whether TMCI is over valued or under valued. Whether Treace Medical Concepts, Inc. is cheap or expensive depends on the assumptions which impact Treace Medical Concepts, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TMCI.

What is Treace Medical Concepts, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, TMCI's PE ratio (Price to Earnings) is -14.39 and Price to Sales (PS) ratio is 3.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TMCI PE ratio will change depending on the future growth rate expectations of investors.